Baseline plasma NfL is a robust prognostic biomarker for spinal cord disease progression in adult X-ALD and supports its use for patient stratification in clinical trials, whereas GFAP shows limited standalone utility.
No takes yet. Share an insight, caveat, or question.
Kabak et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: